10 April 2020 | News
Australia CRO Avance Clinical reveals that the primary reason APAC biotechs chose Australia was the attractive Australian Government financial rebate of more than 40% on clinical trial spend.
Avance Clinical CEO Yvonne Lungershausen with her team
Leading Australian CRO Avance Clinical on 3 April 2020 detailed the top reasons it's APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback.
Avance Clinical is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise.
Avance Clinical said a primary reason that APAC biotechs chose Australia was the attractive Australian Government financial rebate of more than 40% on clinical trial spend.
Avance Clinical CEO Yvonne Lungershausen said this makes good financial sense for biotechs in early clinical phases.
Another key factor is that, during the current COVID-19 pandemic, sites can pivot to patient video visits or telemedicine, which this week got a Government funding boost as part of an AUD$1.1 billion COVID-19 package.
Ms Lungershausen said “This additional funding into an already high-tech medical environment means sites are rapidly able to incorporate telehealth visits to overcome challenges faced by patients not wanting to visit clinics during the pandemic.”
“Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.”
“Avance is the CRO of choice for clinical trials - as well as those targeting COVID-19.”
The top reasons for selecting Australia are:
For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/